Want to see ENGN full AI Analyst Report?
Top Page
enGene Holdings
(NASDAQ:ENGN)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.00
▲(9.89% Upside)
Action:Reiterated
Date:07/18/26
The score is held down primarily by weak financial performance (pre-revenue, widening losses, and deeply negative cash flows) and a poor long-term technical trend with negative momentum. Corporate events provide some upside via program progress and upcoming regulatory milestones, but restructuring and leadership changes add risk; valuation contributes only modest support due to a negative P/E and no dividend.
Positive Factors
Balance Sheet / Cash Runway
A strong cash position plus historically low leverage (debt-to-equity ~0.12) gives enGene durable operating flexibility during late-stage development and regulatory review. This reduces near-term financing pressure and supports execution on pivotal readouts and potential BLA activities.
Negative Factors
Sustained Cash Burn
Persistent, cash-based losses and deeply negative operating/free cash flow imply continued dependence on external funding if revenues do not materialize. This elevates dilution and refinancing risk, meaning capital markets and financing strategy will materially affect long-term shareholder value.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet / Cash Runway
A strong cash position plus historically low leverage (debt-to-equity ~0.12) gives enGene durable operating flexibility during late-stage development and regulatory review. This reduces near-term financing pressure and supports execution on pivotal readouts and potential BLA activities.
Read all positive factors
enGene Holdings (ENGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$119.91M
Dividend YieldN/A
Average Volume (3M)1.07M
Price to Earnings (P/E)―
Beta (1Y)0.52
Revenue GrowthN/A
EPS Growth-32.34%
CountryUS
Employees82
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.32
Shares Outstanding66,989,460
10 Day Avg. Volume866,912
30 Day Avg. Volume1,069,605
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside64.84% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)-1.77
Revenue Forecast (FY)N/A
enGene Holdings Business Overview & Revenue Model
Company Description
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal t...
How the Company Makes Money
null...
enGene Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -369.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -125.94M | -113.80M | -52.04M | -94.77M | -22.78M | -18.14M |
| Net Income | -66.40M | -117.30M | -55.14M | -99.92M | -24.46M | -23.44M |
Balance Sheet | ||||||
| Total Assets | 307.52M | 221.47M | 311.17M | 86.96M | 132.04M | 131.45M |
| Cash, Cash Equivalents and Short-Term Investments | 258.46M | 193.81M | 238.40M | 81.60M | 314.15K | 1.07M |
| Total Debt | 33.35M | 31.80M | 25.02M | 9.78M | 32.11M | 4.16M |
| Total Liabilities | 52.36M | 53.76M | 38.56M | 14.47M | 4.62M | 4.05M |
| Stockholders Equity | 255.17M | 167.71M | 272.61M | 72.49M | 127.42M | 127.39M |
Cash Flow | ||||||
| Free Cash Flow | -111.39M | -100.72M | -49.21M | -25.06M | -17.75M | -16.23M |
| Operating Cash Flow | -110.00M | -99.24M | -48.28M | -24.74M | -17.59M | -15.98M |
| Investing Cash Flow | -60.78M | -25.14M | -125.95M | -318.00K | -153.00K | -247.00K |
| Financing Cash Flow | 143.06M | 1.52M | 265.72M | 86.15M | 27.97M | 22.52M |
enGene Holdings Technical Analysis
Negative
1.82
Price Trends
1.78
Negative
4.00
Negative
6.36
Negative
Market Momentum
-0.06
Negative
41.86
Neutral
27.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENGN, the sentiment is Negative. The current price of 1.82 is below the 20-day moving average (MA) of 1.85, above the 50-day MA of 1.78, and below the 200-day MA of 6.36, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 41.86 is Neutral, neither overbought nor oversold. The STOCH value of 27.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENGN.
enGene Holdings Risk Analysis
enGene Holdings disclosed 84 risk factors in its most recent earnings report. enGene Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
enGene Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $267.20M | -3.53 | -0.11% | ― | ― | 40.79% | |
54 Neutral | $579.11M | -8.95 | -24.73% | ― | ― | 21.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $941.09M | -3.31 | -128.57% | ― | ― | -9.27% | |
47 Neutral | $119.91M | -1.36 | -29.34% | ― | ― | -32.34% | |
46 Neutral | $222.96M | -1.66 | -59.27% | ― | -100.00% | -62.96% | |
45 Neutral | $19.70M | -1.32 | -64.17% | ― | -100.00% | 94.65% |
* Healthcare Sector Average
ENGN
enGene Holdings
1.77
-2.05
-53.66%
TVRD
Tvardi Therapeutics
2.02
-24.32
-92.33%
CAPR
Capricor Therapeutics
4.20
-3.48
-45.31%
REPL
Replimune Group
11.91
6.20
108.58%
IMRX
Immuneering
4.17
0.74
21.57%
CTNM
Contineum Therapeutics, Inc. Class A
15.93
10.13
174.66%
enGene Holdings Corporate Events
Business Operations and StrategyProduct-Related Announcements
enGene Highlights Progress of Lead Bladder Cancer Therapy
Positive
Jul 17, 2026
On July 17, 2026, enGene Therapeutics Inc. updated its corporate presentation outlining progress and expectations for its lead investigational therapy, detalimogene voraplasmid, for non‑muscle‑invasive bladder cancer. The company under...
Business Operations and StrategyExecutive/Board Changes
enGene Holdings appoints new chairman to guide growth
Positive
Jul 17, 2026
On July 15, 2026, longtime chairman Dr. Richard Glickman resigned from enGene Therapeutics’ board, ending more than 14 years of leadership in which he helped steer the company’s DDX platform development and its transition from seed-sta...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
enGene Restructures, Cuts Workforce to Advance Bladder Therapy
Negative
Jun 15, 2026
On June 15, 2026, enGene detailed a sweeping restructuring, including a 50% staff reduction effective June 14, 2026, and halted enrollment in certain LEGEND cohorts to preserve capital as it awaits 12-month durability data and plans a Biologics Li...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
enGene Holdings Shareholders Approve Board and Auditor Slate
Positive
Jun 10, 2026
At its Annual General Meeting held on June 9, 2026, enGene Therapeutics Inc. reported that shareholders representing approximately 83.89% of its 66,989,466 outstanding common shares were present or represented by proxy, underscoring strong investo...
Business Operations and StrategyExecutive/Board ChangesProduct-Related Announcements
enGene Releases Mixed Interim Data from LEGEND Phase 2 Trial
Neutral
May 7, 2026
On May 5, 2026, enGene USA amended and restated the employment agreement with Dr. Hussein Sweiti, effective May 6, 2026, updating his compensation to a $561,750 base salary, a 40% annual bonus opportunity, and continued benefit eligibility. The ne...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.